Cover Image
市場調查報告書

是多發性硬化症市場上市場障礙分析 (美國的情況)

FirstView Barriers - An Analysis of Market Barriers in Multiple Sclerosis (US)

出版商 FirstWord 商品編碼 328746
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
是多發性硬化症市場上市場障礙分析 (美國的情況) FirstView Barriers - An Analysis of Market Barriers in Multiple Sclerosis (US)
出版日期: 2015年03月31日 內容資訊: 英文
簡介

本報告提供美國的多發性硬化症的治療藥的市場上市場進入障礙的影響度相關分析、目前市場規模、用戶基礎,及整體市場的進入障礙 (價格、利用可能性、醫療費償付情形等) 的影響度、各企業/品牌藥由於障礙獲得、損失的市場佔有率的大小等調查、考察。

目前用戶基礎和整體市場障礙的影響度

  • 目前使用概況與考察
  • 整體市場障礙的影響度
  • 障礙伴隨的損失和獲利
  • 障礙效果的測量

在品牌單位的障礙影響

  • 市場佔有率擴大/縮小的原因是什麼?
  • 哪個企業奪去了市場佔有率?
  • 從哪個企業奪取了佔有率?

附錄

  • 醫療專家簡介
  • 障礙效果的評估法:摘要
目錄
Product Code: 596200396

FirstView Barriers - An Analysis of Market Barriers in Multiple Sclerosis (US) provides cutting edge, advanced and proprietary analytics that companies operating in the MS space need to develop, shape and refine brand strategy. FirstView's Market Barriers in MS Report (EU5) is also available.

Critically, the report quantifies the impact and influence of specific environmental barriers - such as price, availability and reimbursement - in relation to how much market share your brand gains and loses, to which brands your share is going to, and from which brands your brand is getting share from.

The proprietary barrier instrument utilizes statistical analysis and advanced calculation to provide you with this precise information. This information allows you to act strategically and focus on the market barriers that can drive market share gains and improve competitiveness for your brand.

Key Issues Expored

  • Each brand's current user base, plus doctors who are not current users but would consider using it
  • In the market, the percentage of prescriptions influenced by barriers, the barriers experienced and the volume of prescriptions these barriers represent
  • Amount of share each brand gains/loses due to the barriers

Market Barriers in MS Reports

FirstView's Market Barriers in MS Report (EU5) is available. If you purchase both the US/EU5 reports you receive an US/EU5 Comparison Review.

  • FirstView Barriers - An Analysis of Market Barriers in Multiple Sclerosis (EU5)
  • FirstView Barriers - An Analysis of Market Barriers in Multiple Sclerosis (US & EU5) which includes a Comparison Review.

Answers to Critical Questions

  • What brands are US physicians prescribing to their MS patients?
  • What is the top market barrier that forces a physician to prescribe a drug they didn't intend to?
  • Which MS drug gains the most and least share due to current market barriers?
  • Which MS drug is benefiting the most from current market barriers?
  • What are the most common barriers in the US that cause a brand to gain and lose market share?

MS Brands Reviewed

  • Avonex (interferon-beta-1a)
  • Rebif (interferon-beta-1a)
  • Betaseron (interferon-beta-1b)
  • Extavia (interferon-beta-1b)
  • Copaxone (glatiramer acetate; including daily and 3x weekly formulations)
  • Gilenya (fingolimod)
  • Tecfidera (dimethyl fumarate)
  • Aubagio (teriflunomide)
  • Tysabri (natalizumab)

Table of Contents

Current user base and overall market barrier impact

  • Current usage and consideration
  • Overall market barrier impact
  • Losses and gains due to barriers
  • Barrier effect score

Brand specific barrier impact

  • Why do I lose or gain share?
  • Who gets my share?
  • Whose share do I get?

Appendix

  • Physician profile
  • Barrier effect score summary
Back to Top